Navigating Next-Generation Cellular Therapies | The 7investing Podcast

Navigating Next-Generation Cellular Therapies

February 3, 2021 – By Samantha Bailey

The first chimeric antigen T-Cell Therapy (CAR-T) therapies were approved by the Federal Drug Administration (FDA) in 2017–these were heralded as “cures” for blood-borne cancers such as acute myeloid leukemia and aggressive non-Hodgkin’s Lymphoma.

Here, we have Simon Harnest, the Senior Vice President of Corporate Strategy and Finance of Cellectis (CLLS), unpacking where cell therapy is headed towards. Cellectis is the first company  to envision an “off-the-shelf” approach to CAR-T therapy. Previous methods required long manufacturing times and complex methodologies to create a single treatment for a patient.

In this episode, Simon guides us through the complexities of creating an allogeneic approach for developing CAR-T therapies, especially for solid tumors, and addresses why Cellectis is up for the challenge. He also addresses the discrepancy between current valuations of Cellectis and competitor, Allogene who happens to license from Cellectis.

This podcast is for anyone interested in learning about the nitty gritty of next generation cancer care from the bottom-up perspective.


Recent Episodes

Overlooked Investing Opportunities with Lawrence Hamtil

7investing Lead Advisor Matthew Cochrane sat down with Lawrence Hamtil, a co-founder of Fortune Financial Advisors, to look at some companies with durable economic moats in...

Investing in Today’s Market with Bill Brewster

Joining 7investing founder Simon Erickson and Lead Advisor Matthew Cochrane to discuss these phenomena is returning guest Bill Brewster, the podcaster extraordinaire who...

7investing Team Podcast: Mission Statements and “Bullish or...

Our 7investing advisor team describes the importance of mission statements in their research process. We also play a game of "Bullish or Bearish" to solicit their thoughts...